BioAtla, Inc. (BCAB)
NASDAQ: BCAB · Real-Time Price · USD
0.3202
+0.0202 (6.73%)
At close: Jan 22, 2026, 4:00 PM EST
0.3333
+0.0131 (4.09%)
After-hours: Jan 22, 2026, 4:51 PM EST
BioAtla Employees
BioAtla had 61 employees as of December 31, 2024. The number of employees decreased by 4 or -6.15% compared to the previous year.
Employees
61
Change (1Y)
-4
Growth (1Y)
-6.15%
Revenue / Employee
n/a
Profits / Employee
-$1,060,770
Market Cap
20.48M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 61 | -4 | -6.15% |
| Dec 31, 2023 | 65 | -1 | -1.52% |
| Dec 31, 2022 | 66 | 10 | 17.86% |
| Dec 31, 2021 | 56 | 20 | 55.56% |
| Dec 31, 2020 | 36 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CASI Pharmaceuticals | 233 |
| CollPlant Biotechnologies | 57 |
| Lunai Bioworks | 29 |
| OSR Holdings | 21 |
| VYNE Therapeutics | 13 |
| ProMIS Neurosciences | 8 |
| Traws Pharma | 7 |
| Allarity Therapeutics | 7 |
BCAB News
- 22 days ago - BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) - GlobeNewsWire
- 2 months ago - BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing - GlobeNewsWire
- 2 months ago - BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress - GlobeNewsWire
- 2 months ago - BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas - GlobeNewsWire
- 2 months ago - BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025 - GlobeNewsWire
- 3 months ago - BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society - GlobeNewsWire
- 3 months ago - BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025 - GlobeNewsWire